About Carbylan
Carbylan is a publicly listed company based in Palo Alto (United States) founded in 2004. Hyaluronic acid polymers are developed into therapeutics for pain management. Carbylan has raised $42.9 million across 6 funding rounds from investors including Alta Partners, InterWest and Vivo Capital. The company has 7 employees. Its focus areas include Life Sciences, Neurology, Drugs and Pain. Its legal entity is KALVISTA PHARMACEUTICALS, INC. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
Carbylan develops therapeutics using polymers of hyaluronic acid. Its proprietary technology enables the crosslinking of hyaluronic acid to form hydrogels. Its lead candidate Hydros-TA is a low dose steroid - hydrogel formulation for pain management with symptomatic osteoarthritis (Phase 3). In Apr 2016, Carbylan pulls pain drug Phase 3 trial and puts itself up for sale. As of Nov 2016, Carbylan Therapeutics was acquired by KalVista Pharmaceuticals in a reverse merger transaction.
- Headquarters Palo Alto, United States
- Employees 7
- Stage Public
- SectorsHealthcare
- Website carbylan.com
- Social LinkedIn X
- Legal Name Kalvista Pharmaceuticals, Inc.
- Total Equity Funding$42.9M (USD)
in 6 rounds
- Latest Funding Round$4M (USD), Series C
Mar 2015
- InvestorsAlta Partners
& 2 more
- Employee Count7
Funding Insights of Carbylan
Carbylan has successfully raised a total of $42.9M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $4 million completed in March 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $42.9M
- Total Rounds 6
- Last Round Series C — $4M
- First Round $7.75M
(Dec 2005)
- Investors Count 3
All 6 funding rounds of Carbylan with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2015 | $4M | Series C | – | – | – |
| Oct 2014 | $5M | Series C | – | – | – |
| Jan 2013 | $6M | Series C | – | – | |
| Nov 2007 | $20M | Series B | – | – | |
| Dec 2005 | $7.75M | Series A | – | – | – |
| Dec 2005 | $152,868 | Series A | – | – | – |
3 investors in total: 3 institutional.
Investors in Carbylan
Carbylan has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Alta Partners, InterWest and Vivo Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Early-stage investing in IT and healthcare ventures. | interwest.com | |||
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States |
Investor details for Carbylan
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Carbylan
97 people are tracked at Carbylan (61 in leadership, 4 in board & advisors, 32 in team); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
T. Andrew Crockett | CEO | Leadership |
Edward P. Feener | Chief Scientific Officer | Leadership |
Sam O. | Global Head Clinical Safety And Pharmacovigilance | Leadership |
Kara Goldman | Senior Sales Director | Leadership |
Manny Gaspar | Vice President, Sales And Marketing | Leadership |
April Vecchio | Director, Market Access Strategy & Effectiveness | Leadership |
Paul K. Audhya | Chief Medical Officer | Leadership |
Christopher M. Yea | Chief Development Officer | Leadership |
Keith Tennison | Vice President Of Market Access | Leadership |
Gregg Robinson | Vice President - US Marketing | Leadership |
Markus Heckmann | Executive Director, Head Of Global Marketing | Leadership |
Linda Härndahl | Associate Director Project Management | Leadership |
Jt Newton | Senior Director, Commercial Effectiveness & Training | Leadership |
Dave Lauinger | Senior Sales Director - West | Leadership |
Jennifer Richards | Director GXP Quality | Leadership |
Edith Mercenier | EU Commercial Operations Lead, Associate Director | Leadership |
Nicole Sweeny | Chief Commercial Officer | Leadership |
Melinda L. Hurley | Director, Commercial Finance | Leadership |
Allen Clermont | Director, Preclinical Pharmacology | Leadership |
Johannah Sharman | Director | Leadership |
77 more people are available in the full profile.
Complete people profiles for Carbylan
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Carbylan
Carbylan is a publicly listed company on the NASDAQ with ticker symbol KALV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Apr 2015
- Listed onNASDAQ: KALV
- Listed entityKalVista Pharmaceuticals, Inc.
- Exchange sectorHealth technology
Timeline of Carbylan
4 dated milestones of Carbylan across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Carbylan is founded.
- Funding First funding round of $7.8M.
- Funding Latest funding round, Series C, of $4.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Carbylan
Carbylan has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of Carbylan
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Carbylan (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Carbylan
Carbylan was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Carbylan is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Carbylan is a funded company, having raised a total of $42.9M across 6 funding rounds to date. The company's 1st funding round was a Series A of $7.75M, raised on Dec 2005.
Carbylan has 7 employees.
Carbylan develops therapeutics using polymers of hyaluronic acid. Its proprietary technology enables the crosslinking of hyaluronic acid to form hydrogels. Its lead candidate Hydros-TA is a low dose steroid - hydrogel formulation for pain management with symptomatic osteoarthritis (Phase 3). In Apr 2016, Carbylan pulls pain drug Phase 3 trial and puts itself up for sale. As of Nov 2016, Carbylan Therapeutics was acquired by KalVista Pharmaceuticals in a reverse merger transaction.
Carbylan's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Yes, Carbylan is publicly traded on NASDAQ under the ticker symbol KALV.
Carbylan has 3 investors. Key investors include Alta Partners, InterWest, and Vivo Capital.
Carbylan operates through Kalvista Pharmaceuticals, Inc..